Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Teun van de Laar, former vice president of chemistry, manufacturing and controls at Aduro Biotech, has been named vice president of manufacturing at AM-Pharma. Maarten Kraan was also recently hired by AM-Pharma to the role of chief medical officer. Kraan was most recently head of R&D at Pierre Fabre.
João Siffert, former CEO of Abeona Therapeutics, has been named CEO of Design Therapeutics.
Chris Galloway has been named chief medical officer of Diffusion Pharmaceuticals. Galloway was most recently senior medical director at La Jolla Pharmaceuticals.
Premal Patel, former chief medical officer at Lyell Immunopharma, has been named chief medical officer of eFFECTOR.
Pharmaceutical company Enterin has appointed David McCullough to lead the company as its CEO. McCullough was previously president and managing director of Allergopharma.
EXUMA Biotech has appointed Sid Kerkar to vice president of oncology and R&D. Formerly, Kerkar was associate vice president of immuno-oncology at Eli Lilly.
Moya Daniels has been appointed executive vice president and head of regulatory, quality and clinical operations at Histogen. Most recently, Daniels served as senior vice president of good manufacturing practices at SanBio.
President of Janssen Japan, Chris Hourigan, has been promoted to company group chairman for Janssen Asia Pacific. Hourigan has been the president of Janssen Japan the past five years.
Danny Bar-Zohar will replace newly retired Luciano Rossetti as global head of R&D for healthcare at Merck KGaA. Bar-Zohar was previously global head of clinical development and analytics at Novartis.
Heidi Petersen has been named senior vice president of regulatory affairs at Mereo BioPharma. Petersen joins Mereo from Kartos Therapeutics, where she served as vice president of regulatory affairs.
Gregory Block has been appointed senior vice president of corporate development of Notch Therapeutics. Block most recently was the director of business development for Astellas Pharmaceuticals.
Chris Nowers has taken the helm of ONK Therapeutics as its new CEO. Prior to ONK, Nowers was CEO of Cell Medica.
Raymond Urbanski has been named U.S. head of clinical development and medical affairs at PharmaEssentia. Most recently, Urbanski was chief medical officer and president of GT Biopharma.
Steve Orndorff has been named COO of Renew Biopharma. Prior to this appointment, Orndorff was COO of Teewinot Life Sciences.
Dania Rabah, former Biogen head of drug discovery research and early development, has been appointed chief scientific officer at Rheos Medicines.
Selexis has named Dirk Lange as its new CEO. Lange will continue to serve as president and CEO of KBI Biopharma.
SparingVision has appointed Stéphane Boissel as its new CEO. Boissel was executive vice president of corporate strategy at Sangamo Therapeutics prior to joining SparingVision.
Topas Therapeutics has tapped Klaus Martin to lead the company as CEO. Martin was president of Apobiologix prior to joining Topas.